Tasigna (nilotinib), FDA-Approved for Philadelphia Chromosome Positive CML
Filed in archive Cancer , FDA Approvals , Treatment on October 30, 2007
Novartis Pharma's Tasigna (nilotinib) has recently been approved by the US FDA for the treatment of Philadelphia chromosome positive chronic myeloid leukemia (CML) in adult patients whose disease has progressed on or who cannot tolerate other therapies that included imatinib (Gleevec).

FDA's approval of Tasigna includes a black box warning for possible life-threatening heart problems that may lead to an irregular heartbeat and possible sudden death.
The effectiveness of Tasigna is based on response rates observed in an ongoing clinical trial. Responses are associated with normalization of blood counts and bone marrow examinations. Further follow-up of patients is needed to determine how long these responses will last.
The abnormal chromosome called the Philadelphia chromosome is located in the leukemic cells and is present in the majority of CML patients. CML accounts for 15 percent of all leukemias in adults.
Find more details from the FDA News.
The effectiveness of Tasigna is based on response rates observed in an ongoing clinical trial. Responses are associated with normalization of blood counts and bone marrow examinations. Further follow-up of patients is needed to determine how long these responses will last.
Tags: Tasigna nilotinib philadelphia chromosome positive chronic myeloid leukemia CML health philadelphia+
Vote for Tasigna (nilotinib), FDA-Approved for Philadelphia Chromosome Positive CML:
|
Rating: 6.33 out of 3 vote(s) cast.
|
Most Popular
Allergies
Alzheimer's Disease
Arthritis
Bacteria and Bacterial Infections
Best of
Blog Carnivals
Bone Health
Cancer
Cardiovascular Health
Cases
CFS
Consumer Alert
Controversies
Dental Health
Diabetes
Diagnostics
Diarrhea
Did you know
Diet
Dietary Supplements and Vitamins
